Brain lesions in multiple sclerosis are areas of damage in the central nervous system caused by immune-mediated destruction of myelin, the protective sheath around nerve fibers. These lesions appear as bright spots on T2-weighted and FLAIR MRI sequences and are a core diagnostic feature of MS.
Lesions form when the immune system mistakenly targets myelin in the brain and spinal cord. This process, called demyelination, disrupts electrical signaling between neurons. Over time, repeated episodes lead to scar tissue-called plaques-that interfere with motor control, sensation, cognition, and coordination. The presence and location of lesions correlate with symptom severity and disease progression.
Diagnosis relies heavily on MRI imaging. A single lesion isn't enough to confirm MS; clinicians look for dissemination in space (lesions in multiple brain regions) and time (new lesions appearing over months). The McDonald Criteria, updated in 2017 by the International Panel on Multiple Sclerosis Diagnosis, standardize how lesion patterns support a diagnosis.
The autoimmune attack begins when immune cells cross the blood-brain barrier. Once inside, T-cells and B-cells activate microglia and astrocytes, triggering inflammation. This inflammatory cascade damages oligodendrocytes-the cells that produce myelin-leading to demyelination and subsequent axonal injury.
Lesions evolve through phases: acute inflammation (visible as contrast enhancement on MRI), subacute repair attempts, and chronic scarring. Chronic lesions may show reduced volume due to axonal loss, contributing to permanent disability. Not all lesions cause symptoms; some remain silent until they accumulate or affect critical pathways.
A 2021 study published in Neurology found that patients with high lesion burden (over 10 T2 lesions on baseline MRI) were twice as likely to progress to secondary progressive MS within five years compared to those with fewer lesions. This underscores the clinical value of early lesion detection.
MS lesions primarily occur in white matter but can also affect gray matter and the spinal cord. The most common locations include periventricular regions (around the fluid-filled ventricles), juxtacortical areas (just beneath the cerebral cortex), and the cerebellum.
| Type | Location | Appearance on MRI | Clinical Implication |
|---|---|---|---|
| Periventricular | Surrounding lateral ventricles | Round or ovoid, often "Dawson's fingers" along vein tracts | Highly specific for MS; associated with cognitive decline |
| Juxtacortical | At the gray-white matter junction | Clipped or crescent-shaped | Indicates cortical involvement; linked to memory and attention deficits |
| Infratentorial | Brainstem and cerebellum | Small, irregular, often bilateral | Associated with vertigo, nystagmus, and ataxia |
| Spinal cord | Cervical and thoracic segments | Hyperintense on T2, may show cord expansion | Linked to leg weakness, bladder dysfunction |
Lesions in the corpus callosum-connecting the brain's hemispheres-are particularly telling. Their presence increases diagnostic confidence, especially when combined with other MRI features.
Many assume all brain lesions are cancerous or indicative of stroke. In MS, lesions are non-neoplastic and result from immune activity, not vascular events. Stroke lesions typically follow arterial territories and resolve faster; MS lesions are scattered and persistent.
Another misunderstanding is that lesion count equals symptom severity. While higher lesion load correlates with greater disability risk, some individuals with many lesions remain mildly symptomatic. Conversely, a few lesions in critical areas-like the optic nerve or corticospinal tracts-can cause severe deficits.
A key distinction: not all white matter abnormalities are MS-related. Conditions like small vessel ischemic disease, infections (e.g., toxoplasmosis), or neuromyelitis optica spectrum disorder (NMOSD) can mimic MS lesions. Differentiating requires clinical context, CSF analysis, and sometimes advanced imaging such as diffusion tensor imaging (DTI).
In 2019, a 32-year-old woman presented with blurred vision and unsteady gait. An MRI revealed multiple periventricular and juxtacortical lesions. She had no history of trauma or infection. Lumbar puncture showed elevated IgG index and oligoclonal bands-evidence of intrathecal antibody production. After ruling out NMOSD and Lyme disease, she was diagnosed with relapsing-remitting MS.
She began treatment with interferon beta-1a. Six months later, follow-up MRI showed no new lesions and stabilization of existing ones. Her symptoms improved. This case illustrates how lesion monitoring guides therapy decisions and tracks response.
During a neurology rotation, I observed a patient whose initial MRI showed only one lesion. Over 18 months, new lesions emerged in different brain regions. Only then did the diagnosis meet McDonald Criteria for dissemination in space. This highlights that lesion development over time is as important as their number.
Anyone experiencing unexplained neurological symptoms-such as vision loss, limb weakness, balance issues, or cognitive fog-should undergo neuroimaging if MS is suspected. Early detection allows timely intervention to slow progression.
Lesions detected incidentally during scans for unrelated reasons (e.g., headaches or dizziness) should be evaluated carefully. A 2020 study in Multiple Sclerosis Journal reported that 15% of asymptomatic adults with incidental white matter lesions later developed MS within ten years, especially if lesions were periventricular or multifocal.
Brain lesions in MS are not just imaging artifacts-they are biological markers of ongoing disease activity. Understanding their nature, distribution, and evolution enables accurate diagnosis, effective treatment planning, and better long-term outcomes.